Physician
Jalil, Tania
Jalil, Tania was paid $4.99M by Medicaid between Jan 2018 and Dec 2024, across 81 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 22% of everything it billed.
33Billing provider infoJALIL, TANIA
BROWNSVILLE, TX 78526
BROWNSVILLE, TX 78526
33aNPI1336125046assigned 12/15/2005
33bProvider typePediatrics Physician
28Total paid$4.99M
24GClaims314,585
24DCodes billed81
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Texas
Rank by total paid#82 of 1,136
Median peer was paid$329K
This provider vs. median15×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 862 | $15K | |
| 2019 | 1,459 | $24K | |
| 2020 | 21,204 | $308K | |
| 2021 | 81,926 | $1.14M | |
| 2022 | 90,507 | $1.43M | |
| 2023 | 71,191 | $1.28M | |
| 2024incomplete | 47,436 | $794K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 22% | 47,081 | 34,468 | $1.12M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 9.3% | 29,193 | 23,970 | $465K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 7.9% | 10,352 | 9,304 | $395K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 7.6% | 4,631 | 4,523 | $382K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 7.3% | 4,639 | 4,473 | $364K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 6.6% | 4,002 | 3,781 | $330K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 6.5% | 2,552 | 2,392 | $324K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 6.0% | 28,470 | 12,733 | $298K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 5.1% | 3,289 | 3,009 | $252K |
| 99050 | 3.5% | 12,242 | 10,059 | $173K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2.4% | 13,777 | 12,724 | $121K |
| 99000 | 2.4% | 17,542 | 15,657 | $119K |
69 more codes
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.0% | 14,076 | $100K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 16,600 | $71K |
| 99429 | 1.2% | 1,763 | $58K | |
| 92558 | <1% | 11,369 | $45K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 5,074 | $41K |
| 99051 | <1% | 9,031 | $35K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,112 | $30K |
| 81002 | <1% | 12,009 | $24K | |
| 0071A | <1% | 506 | $20K | |
| 90461 | <1% | 2,946 | $19K | |
| 0072A | <1% | 460 | $18K | |
| 99381 | <1% | 220 | $17K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 304 | $15K |
| 80061 | Lipid panel | <1% | 2,057 | $14K |
| 87807 | <1% | 2,224 | $14K | |
| 0001A | <1% | 313 | $12K | |
| 90480 | <1% | 426 | $11K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,751 | $11K |
| 0144A | <1% | 226 | $9K | |
| 0002A | <1% | 221 | $9K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 112 | $9K |
| 0134A | <1% | 238 | $9K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 918 | $7K |
| 96160 | <1% | 4,404 | $7K | |
| 0081A | <1% | 181 | $7K | |
| 92567 | <1% | 953 | $7K | |
| 0003A | <1% | 165 | $6K | |
| 0073A | <1% | 138 | $5K | |
| 86580 | <1% | 1,188 | $5K | |
| 82950 | <1% | 1,778 | $4K | |
| 0164A | <1% | 102 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,982 | $4K |
| 0082A | <1% | 88 | $4K | |
| 97169 | <1% | 153 | $3K | |
| 97170 | <1% | 113 | $1K | |
| 99383 | <1% | 14 | $1K | |
| 96380 | <1% | 26 | $267.26 | |
| 84030 | <1% | 86 | $204.50 | |
| 90686 | <1% | 1,261 | $39.40 | |
| 90658 | <1% | 4,366 | $37.66 | |
| G9716 | Bmi is documented as being outside of normal parameters, follow-up plan is not completed for documented medical reason | <1% | 44 | $32.50 |
| 94760 | <1% | 177 | $10.09 | |
| 90620 | <1% | 614 | $0.13 | |
| 90677 | <1% | 396 | $0.07 | |
| 90651 | <1% | 955 | $0.03 | |
| 90734 | <1% | 867 | $0.02 | |
| 90656 | <1% | 566 | $0.02 | |
| 90715 | <1% | 193 | $0.01 | |
| 90670 | <1% | 1,850 | $0.01 | |
| 91322 | <1% | 91 | $0.01 | |
| 90744 | <1% | 926 | $0.01 | |
| 90707 | 0% | 991 | $0.00 | |
| 99173 | 0% | 13,760 | $0.00 | |
| 90713 | 0% | 2,275 | $0.00 | |
| 90700 | 0% | 2,989 | $0.00 | |
| 91321 | 0% | 226 | $0.00 | |
| 90633 | 0% | 1,073 | $0.00 | |
| 91308 | 0% | 394 | $0.00 | |
| 91300 | 0% | 899 | $0.00 | |
| 90380 | 0% | 32 | $0.00 | |
| 91313 | 0% | 237 | $0.00 | |
| 90655 | 0% | 54 | $0.00 | |
| 91316 | 0% | 103 | $0.00 | |
| 90716 | 0% | 993 | $0.00 | |
| 90647 | 0% | 2,279 | $0.00 | |
| 90680 | 0% | 1,339 | $0.00 | |
| 91314 | 0% | 224 | $0.00 | |
| 91307 | 0% | 1,256 | $0.00 | |
| 90381 | 0% | 58 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.